Navigation Links
QB3-Industry Biotech Startup Partnership Funds Two Projects
Date:4/20/2012

SAN FRANCISCO, April 20, 2012 /PRNewswire-USNewswire/ -- The Johnson & Johnson Corporate Office of Science & Technology (COSAT) has funded two research efforts in a program aimed at creating biomedical startup companies at the University of California.

These are the first projects supported by COSAT through the ongoing Bridging-the-Gap award program at the California Institute for Quantitative Biosciences (QB3). COSAT and the Rogers Family Foundation of Oakland jointly fund the Bridging-the-Gap program, which provides nearly $1 million a year for targeted research designed to move projects further along the path to commercialization.

"This is a new model for industry to access innovation as it matures from an academic project to a commercial venture," said Neena Kadaba, QB3's director of industry alliances. "Startups are often the most efficient way of getting discoveries to market, and programs like this allow established companies to build early relationships and partnerships with startups as they form."

The two projects were selected because the research had commercial potential and the lead scientists were keen on starting companies.

The first project, to develop a synthetic capsule for the treatment of Type I diabetes, is directed by Shuvo Roy, associate professor of bioengineering and therapeutic sciences at the University of California, San Francisco (UCSF), and based on membrane technology used in a prototype artificial kidney invented by Roy.

The second project is a collaboration between Scott Lokey, associate professor of chemistry at UC Santa Cruz, and Matt Jacobson, professor of pharmaceutical chemistry at UCSF. It combines computer modeling and benchtop synthesis of "cyclic peptides," which can affect how proteins interact with each other. The research has therapeutic applications.

QB3 provides Bridging-the-Gap winners with services from the QB3 Startup-In-A-Box program, and, potentially, space in the QB3 incubator system (the QB3 Garage/Innovation Network) for spinoff companies arising from the projects.

The nine projects funded by QB3's Bridging-the-Gap program to date have resulted in five new companies and three licenses to existing firms. The five companies formed in the past two years have raised over $9 million in private and public commercial funding.

In the 2012 Bridging-the-Gap award cycle, the Rogers Foundation has also funded three new projects.

QB3 is a cooperative effort among private industry and more than 220 scientists at UCSF, UC Berkeley and UC Santa Cruz. QB3 has a joint mission of supporting science, driving the California economy and transforming scientific research into public good. Fundamental to the latter two missions are QB3's efforts to commercialize University of California science by creating mutually beneficial partnerships with industry and supporting innovative entrepreneurs. The effort has led to 60 bioscience startup companies in the QB3 Garage/Innovation Network, which have raised $225 million and created more than 280 jobs. QB3 also operates Mission Bay Capital, an $11.3M seed-stage venture capital fund designed to help UC entrepreneurs create successful startups. Please visit www.qb3.org.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. Please visit www.ucsf.edu.

For more information on the Johnson & Johnson Corporate Office of Science and Technology (COSAT), visit www.jnjcosat.com/cosat.


'/>"/>
SOURCE QB3
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program
2. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
3. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
4. Charlie Wilson Teams Up With Janssen Biotech to Launch Making Awareness a Priority (M.A.P.)
5. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
6. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
7. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
8. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
9. Global Biotechnology Industry
10. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
11. JumpStart Invests $250,000 in Milo Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):